Dofequidar

Dofequidar

CAT N°: 30925
Price:

From 66.00 56.10

Dofequidar is a quinoline derivative and inhibitor of multidrug resistance.{53975,53976} It inhibits P-glycoprotein in a photolabeling assay when used at a concentration of 100 ?M.{53975} Dofequidar (10 ?M) increases intracellular accumulation of [3H]-vincristine in HL-60R cells endogenously expressing the gene encoding multidrug resistance-associated protein (MRP).{53976} It restores susceptibility to vincristine- or doxorubicin-induced cytotoxicity in vincristine-resistant P388, vincristine-resistant K562, and doxorubicin-resistant K562 cells in a concentration-dependent manner.{53975} Dofequidar (80 mg/kg twice per day) increases survival in a vincristine-resistant P388 murine leukemia model compared with untreated controls when administered in combination with vincristine (Item No. 11764).

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 1-[4-[2-hydroxy-3-(5-quinolinyloxy)propyl]-1-piperazinyl]-2,2-diphenyl-ethanone
  • Correlated keywords
    • MS-209 MS209 multi-drug glyco-protein HL60R P-388 K-562
  • Product Overview:
    Dofequidar is a quinoline derivative and inhibitor of multidrug resistance.{53975,53976} It inhibits P-glycoprotein in a photolabeling assay when used at a concentration of 100 ?M.{53975} Dofequidar (10 ?M) increases intracellular accumulation of [3H]-vincristine in HL-60R cells endogenously expressing the gene encoding multidrug resistance-associated protein (MRP).{53976} It restores susceptibility to vincristine- or doxorubicin-induced cytotoxicity in vincristine-resistant P388, vincristine-resistant K562, and doxorubicin-resistant K562 cells in a concentration-dependent manner.{53975} Dofequidar (80 mg/kg twice per day) increases survival in a vincristine-resistant P388 murine leukemia model compared with untreated controls when administered in combination with vincristine (Item No. 11764).

We also advise you